Compound Planning Inc. Raises Position in Boston Scientific Corporation $BSX

Compound Planning Inc. increased its holdings in Boston Scientific Corporation (NYSE:BSX) by 9.0% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,495 shares of the medical equipment provider’s stock after purchasing an additional 864 shares during the quarter. Compound Planning Inc.’s holdings in Boston Scientific were worth $1,059,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in BSX. Brighton Jones LLC grew its holdings in Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares during the last quarter. Bank Pictet & Cie Europe AG grew its holdings in Boston Scientific by 40.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider’s stock worth $6,529,000 after acquiring an additional 21,173 shares during the last quarter. Highview Capital Management LLC DE grew its holdings in Boston Scientific by 6.2% in the 4th quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider’s stock worth $2,189,000 after acquiring an additional 1,439 shares during the last quarter. Integrated Wealth Concepts LLC grew its holdings in Boston Scientific by 2.7% in the 4th quarter. Integrated Wealth Concepts LLC now owns 16,140 shares of the medical equipment provider’s stock worth $1,442,000 after acquiring an additional 417 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC grew its holdings in Boston Scientific by 0.9% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 19,691 shares of the medical equipment provider’s stock worth $1,759,000 after acquiring an additional 178 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Truist Financial raised their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. Jefferies Financial Group reissued a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Erste Group Bank upgraded shares of Boston Scientific to a “strong-buy” rating in a research report on Thursday, May 8th. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, April 29th. Finally, Barclays boosted their price target on shares of Boston Scientific from $125.00 to $133.00 and gave the company an “overweight” rating in a research report on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $117.50.

Insiders Place Their Bets

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the sale, the executive vice president owned 178,342 shares in the company, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael F. Mahoney sold 164,443 shares of the company’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the completion of the sale, the chief executive officer owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. This trade represents a 10.02% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 345,029 shares of company stock valued at $35,976,603. Insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.7%

NYSE:BSX opened at $105.9950 on Friday. The firm has a market capitalization of $157.06 billion, a P/E ratio of 63.09, a PEG ratio of 2.56 and a beta of 0.66. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a one year low of $78.53 and a one year high of $108.94. The company’s 50-day simple moving average is $104.10 and its 200 day simple moving average is $102.14.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business’s revenue was up 22.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.